ProSanos Corporation announced today the release of Sfetyworks™, a web-based, semi-automated software system that can help scientists more quickly spot and measure the strength of associations between a drug and a medical condition found within large electronic healthcare databases. Sfetyworks™ resulted from a partnership between GlaxoSmithKline plc (GSK) and ProSanos. Several years in development, it is now available to all pharmacovigilance professionals.
HARRISBURG, Pa. (Business Wire EON) August 12, 2008 -- The new software system, pioneered by GSK and ProSanos, is an efficient way to perform active drug surveillance and complement traditional epidemiologic studies. Using Sfetyworks™, drug safety experts will have the unprecedented ability to ask the same questions of different databases. Data from traditional sources, like adverse event reports and epidemiological studies, can quickly and reliably be compared with information from observational sources like insurance claims and electronic medical records. In addition, pharmacovigilance professionals will be able to control for multiple confounding factors, helping them to quickly distinguish unusual conditions that may be associated with a drug from conditions that are disease-related or limited to specific cohorts of patients.
Commenting on the co-development collaboration with ProSanos, Edward Pattishall, MD, VP Safety at GSK stated, "GSK is committed to enhancing patient safety and anticipates this tool will be extremely helpful in evaluating the benefit/risk profile of our medicines using multiple data sources that can't currently be easily and quickly compared.
It is an improvement over other software solutions because it can rapidly and simultaneously interrogate multiple databases and contribute to the evidence of a potential safety issue. We have made an up-front investment in devel
'/>"/>
| Source: PRWeb Copyright©2008 Vocus, Inc. All rights reserved |